Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron DeficiencyFERRIC-HF: A Randomized, Controlled, Observer-Blinded Trial
Darlington O. Okonko, BSc, MRCP*,2,3,4,5,*,
Agnieszka Grzeslo, MD ,4,
Tomasz Witkowski, MD,
Amit K.J. Mandal, MRCP ,
Robert M. Slater, MBBS,
Michael Roughton, MSc*,
Gabor Foldes, MD, PhD*,
Thomas Thum, MD*, ,
Jacek Majda, MD,
Waldemar Banasiak, MD, PhD,
Constantinos G. Missouris, MD,
Philip A. Poole-Wilson, MD, FMedSci*,2,5,7,
Stefan D. Anker, MD, PhD*,||,1,2,6 and
Piotr Ponikowski, MD, PhD,1,2,6
* Clinical Cardiology, NHLI, Imperial College London, London, United Kingdom
Cardiac Department, Military Hospital, Wroclaw, Poland
Department of Cardiology, Wexham Park Hospital, Slough, United Kingdom
Department of Cardiology, Julius-Maximilians University, Würzburg, Germany
|| Division of Applied Cachexia Research, Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany.
View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Individual Changes in Exercise Tolerance With Iron Therapy
Treatment effect of intravenous (IV) iron on (A) absolute peak oxygen consumption (VO
2) and (B) peak VO
2/kg in anemic (bold lines) and nonanemic (dashed lines) subjects. Bars correspond to mean ± SD.
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Correlates of Exercise Performance
Relation between changes in absolute peak oxygen consumption (VO
2) and (A) changes in hemoglobin concentration (r = 0.17; p = 0.43 for intravenous [IV] iron group on removal of outlier [arrow]) and (B) changes in transferrin saturation in the total population.
|
|
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Effect of Iron Therapy on Symptoms and Quality of Life
Effect of treatment on (A) visual analog fatigue score, (B) New York Heart Association (NYHA) functional class, (C) patient global assessment, and (D) Minnesota Living With Heart Failure Questionnaire (MLHFQ) score in the total population. Data are shown as mean ± SD. *p < 0.05; p < 0.01 compared with baseline.
|
|
|
